Forte Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Forte Biosciences has a total shareholder equity of $38.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $47.5M and $9.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$45.86m |
| Equity | US$38.43m |
| Total liabilities | US$9.03m |
| Total assets | US$47.46m |
Recent financial health updates
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Apr 19
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Recent updates
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Apr 19We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Financial Position Analysis
Short Term Liabilities: FBRX's short term assets ($47.2M) exceed its short term liabilities ($9.0M).
Long Term Liabilities: FBRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FBRX is debt free.
Reducing Debt: FBRX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FBRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FBRX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 10:34 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Forte Biosciences, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |
| Keay Nakae | Chardan Capital Markets, LLC |